|
1
|
Lozano R, Naghavi M, Foreman K, Lim S,
Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, et
al: Global and regional mortality from 235 causes of death for 20
age groups in 1990 and 2010: a systematic analysis for the Global
Burden of Disease Study 2010. Lancet. 380:2095–2128. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Moyer VA: USA Preventive Services Task
Force: Screening for ovarian cancer: USA Preventive Services Task
Force reaffirmation recommendation statement. Ann Intern Med.
157:900–904. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vo C and Carney ME: Ovarian cancer
hormonal and environmental risk effect. Obstet Gynecol Clin North
Am. 34:687–700. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hunn J and Rodriguez GC: Ovarian cancer:
etiology, risk factors, and epidemiology. Clin Obstet Gynecol.
55:3–23. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gilbert L, Basso O, Sampalis J, Karp I,
Martins C, Feng J, Piedimonte S, Quintal L, Ramanakumar AV and
Takefman J; DOvE Study Group: Assessment of symptomatic women for
early diagnosis of ovarian cancer: results from the prospective
DOvE pilot project. Lancet Oncol. 13:285–291. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hennessy BT, Coleman RL and Markman M:
Ovarian cancer. Lancet. 374:1371–1382. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hu J, Shao S, Song Y, Zhao J, Dong Y, Gong
L and Yang P: Hepatocyte growth factor induces invasion and
migration of ovarian cancer cells by decreasing the expression of
E-cadherin, beta-catenin, and caveolin-1. Anat Rec (Hoboken).
293:1134–1139. 2010. View
Article : Google Scholar
|
|
8
|
Fader AN and Rose PG: Role of surgery in
ovarian carcinoma. J Clin Oncol. 25:2873–2883. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gur S, Kadowitz PJ and Hellstrom WJ:
RhoA/Rho-kinase as a therapeutic target for the male urogenital
tract. J Sex Med. 8:675–687. 2011. View Article : Google Scholar
|
|
10
|
Rathinam R, Berrier A and Alahari SK: Role
of Rho GTPases and their regulators in cancer progression. Front
Biosci (Landmark Ed). 16:2561–2571. 2011. View Article : Google Scholar
|
|
11
|
Kwiatkowska A and Symons M: Signaling
determinants of glioma cell invasion. Adv Exp Med Biol.
986:121–141. 2013. View Article : Google Scholar
|
|
12
|
Oh HK, Sin JI, Choi J, Park SH, Lee TS and
Choi YS: Overexpression of CD73 in epithelial ovarian carcinoma is
associated with better prognosis, lower stage, better
differentiation and lower regulatory T cell infiltration. J Gynecol
Oncol. 23:274–281. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Takami Y, Higashi M, Kumagai S, Kuo PC,
Kawana H, Koda K, Miyazaki M and Harigaya K: The activity of RhoA
is correlated with lymph node metastasis in human colorectal
cancer. Dig Dis Sci. 53:467–473. 2008. View Article : Google Scholar
|
|
14
|
Zhao X, Lu L, Pokhriyal N, Ma H, Duan L,
Lin S, Jafari N, Band H and Band V: Overexpression of RhoA induces
preneo-plastic transformation of primary mammary epithelial cells.
Cancer Res. 69:483–491. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Friesland A, Zhao Y, Chen YH, Wang L, Zhou
H and Lu Q: Small molecule targeting Cdc42-intersectin interaction
disrupts Golgi organization and suppresses cell motility. Proc Natl
Acad Sci USA. 110:1261–1266. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li J, Tang LD, Tang WX and Ng SW:
Expression and significance of RhoA protein in epithelial ovarian
cancer cells. J Endocr Surg. 3:147–153. 2008.In Chinese.
|
|
17
|
Xing L, Yao X, Williams KR and Bassell GJ:
Negative regulation of RhoA translation and signaling by hnRNP-Q1
affects cellular morphogenesis. Mol Biol Cell. 23:1500–1509. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shimada T, Nishimura Y, Nishiuma T,
Rikitake Y, Hirase T and Yokoyama M: Adenoviral transfer of rho
family proteins to lung cancer cells ameliorates cell proliferation
and motility and increases apoptotic change. Kobe J Med Sci.
53:125–134. 2007.PubMed/NCBI
|
|
19
|
Wang H, Zhao G, Liu X, Sui A, Yang K, Yao
R, Wang Z and Shi Q: Silencing of RhoA and RhoC expression by RNA
interference suppresses human colorectal carcinoma growth in vivo.
J Exp Clin Cancer Res. 29:1232010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li QQ, Skinner J and Bennett JE:
Evaluation of reference genes for real-time quantitative PCR
studies in Candida glabrata following azole treatment. BMC Mol
Biol. 13:222012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ali HM, Urbinati G, Raouane M and
Massaad-Massade L: Significance and applications of nanoparticles
in siRNA delivery for cancer therapy. Expert Rev Clin Pharmacol.
5:403–412. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kelly P, Stemmle LN, Madden JF, Fields TA,
Daaka Y and Casey PJ: A role for the G12 family of heterotrimeric G
proteins in prostate cancer invasion. J Biol Chem. 281:26483–26490.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kelly P, Moeller BJ, Juneja J, Booden MA,
Der CJ, Daaka Y, Dewhirst MW, Fields TA and Casey PJ: The G12
family of heterotrimeric G proteins promotes breast cancer invasion
and metastasis. Proc Natl Acad Sci USA. 103:8173–8178. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Basu Roy UK, Henkhaus RS, Loupakis F,
Cremolini C, Gerner EW and Ignatenko NA: Caveolin-1 is a novel
regulator of K-RAS-dependent migration in colon carcinogenesis. Int
J Cancer. 133:43–57. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nikonova E, Tsyganov MA, Kolch W, Fey D
and Kholodenko BN: Control of the G-protein cascade dynamics by GDP
dissociation inhibitors. Mol Biosyst. 9:2454–2462. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Struckhoff AP, Rana MK and Worthylake RA:
RhoA can lead the way in tumor cell invasion and metastasis. Front
Biosci (Landmark Ed). 16:1915–1926. 2011. View Article : Google Scholar
|
|
27
|
Fiordalisi JJ, Keller PJ and Cox AD: PRL
tyrosine phosphatases regulate rho family GTPases to promote
invasion and motility. Cancer Res. 66:3153–3161. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Olson MF, Ashworth A and Hall A: An
essential role for Rho, Rac, and dc42 GTPases in cell cycle
progression through G1. Science. 269:1270–1272. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Burridge K and Wennerberg K: Rho and Rac
take center stage. Cell. 116:167–179. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gómez del Pulgar T, Benitah SA, Valerón
PF, Espina C and Lacal JC: Rho GTPase expression in tumourigenesis:
evidence for a significant link. BioEssays. 27:602–613. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Qiu RG, Chen J, McCormick F and Symons M:
A role for Rho in Ras transformation. Proc Natl Acad Sci USA.
92:11781–11785. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sahai E and Marshall CJ: RHO-GTPases and
cancer. Nat Rev Cancer. 2:133–142. 2002. View Article : Google Scholar
|
|
33
|
Chen S, Wang J, Gou WF, Xiu YL, Zheng HC,
Zong ZH, Takano Y and Zhao Y: The involvement of RhoA and Wnt-5a in
the tumorigenesis and progression of ovarian epithelial carcinoma.
Int J Mol Sci. s14:24187–24199. 2013. View Article : Google Scholar
|
|
34
|
Ohta T, Takahashi T, Shibuya T, Amita M,
Henmi N, Takahashi K and Kurachi H: Inhibition of the Rho/ROCK
pathway enhances the efficacy of cisplatin through the blockage of
hypoxia-inducible factor-1α in human ovarian cancer cells. Cancer
Biol Ther. 13:25–33. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Canet B, Pons C, Espinosa I and Prat J:
Ovarian clear cell carcinomas: RHO GTPases may contribute to
explain their singular biologic behavior. Hum Pathol. 42:833–839.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gest C, Mirshahi P, Li H, Pritchard LL,
Joimel U, Blot E, Chidiac J, Poletto B, Vannier JP, Varin R, et al:
Ovarian cancer: Stat3, RhoA and IGF-IR as therapeutic targets.
Cancer Lett. 317:207–217. 2012. View Article : Google Scholar
|
|
37
|
Horiuchi A, Kikuchi N, Osada R, Wang C,
Hayashi A, Nikaido T and Konishi I: Overexpression of RhoA enhances
peritoneal dissemination: RhoA suppression with lovastatin may be
useful for ovarian cancer. Cancer Sci. 99:2532–2539. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Boudreau RL and Davidson BL: Generation of
hairpin-based RNAi vectors for biological and therapeutic
application. Methods Enzymol. 507:275–296. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Khatri N, Rathi M, Baradia D, Trehan S and
Misra A: In vivo delivery aspects of miRNA, shRNA and siRNA. Crit
Rev Ther Drug Carrier Syst. 29:487–527. 2012. View Article : Google Scholar : PubMed/NCBI
|
